MBX
MBX Biosciences, Inc. Common StockMBX
MBX
About: MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
Employees: 38
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
95.16% more ownership
Funds ownership: 0% [Q2] → 95.16% (+95.16%) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
39%
upside
Avg. target
$37
73%
upside
High target
$44
104%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Jefferies Michael Yee 10% 1-year accuracy 1 / 10 met price target | 62%upside $35 | Buy Initiated | 8 Oct 2024 |
JP Morgan Jessica Fye 39% 1-year accuracy 16 / 41 met price target | 39%upside $30 | Overweight Initiated | 8 Oct 2024 |
Stifel Annabel Samimy 33% 1-year accuracy 4 / 12 met price target | 86%upside $40 | Buy Initiated | 8 Oct 2024 |
Guggenheim Seamus Fernandez 62% 1-year accuracy 8 / 13 met price target | 104%upside $44 | Buy Initiated | 8 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of the last subject's last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the Company's long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist in development for the treatment of post-bariatric hypoglycemia (PBH).
Neutral
GlobeNewsWire
1 month ago
MBX Biosciences to Participate in Upcoming November Investor Conferences
CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its management team will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
2 months ago
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that both the rationale and design of the Phase 2 Avail™ trial of MBX 2109, the Company's potential long-acting parathyroid hormone (PTH) peptide prodrug, in adults with hypoparathyroidism (HP) were featured in a poster presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting held in Toronto, ON, Canada September 27-30, 2024.
Neutral
24/7 Wall Street
3 months ago
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying
24/7 Wall St. Insights Initial public offerings at three biotechs last week tempted insiders to make huge purchases of shares.
Neutral
GlobeNewsWire
3 months ago
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the closing of its previously announced upsized initial public offering of 11,730,000 of its common stock at a price to the public of $16.00 per share, which includes 1,530,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The aggregate gross proceeds to MBX Biosciences from the offering were approximately $187.7 million, before deducting underwriting discounts and commissions and offering expenses.
Positive
Seeking Alpha
3 months ago
U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market
Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand courier service provider BingEx also filed to raise $100 million. No IPOs are currently scheduled to list in the week ahead, as activity remains somewhat muted in the run-up to the 2024 presidential election.
Positive
Reuters
3 months ago
MBX Biosciences shares surge 44% in blockbuster Nasdaq debut
Shares of MBX Biosciences , which is developing therapies that target endocrine and metabolic disorders, including diabetes and obesity, rose nearly 44% in their Nasdaq debut on Friday, underscoring investors' focus on weight-loss drugs.
Positive
Reuters
3 months ago
MBX Biosciences raises $163.2 mln in US IPO
MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including diabetes and obesity, said on Thursday it has raised $163.2 million in its U.S. initial public offering.
Neutral
GlobeNewsWire
3 months ago
MBX Biosciences Announces Pricing of Initial Public Offering
CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its initial public offering of 10,200,000 shares of its common stock at a price to the public of $16.00 per share. The gross proceeds to MBX Biosciences from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $163.2 million. All of the shares are being offered by MBX Biosciences. In addition, MBX Biosciences has granted the underwriters a 30-day option to buy an additional 1,530,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
Charts implemented using Lightweight Charts™